Materias dentro de su búsqueda.
Materias dentro de su búsqueda.
Historia
24
Películas cinematográficas
16
Música popular
13
Novela estadounidense
12
Jazz
10
Música para órgano
7
Crítica e interpretación
6
Música rock
6
Correspondencia
5
Comedy films
4
Condiciones sociales
4
Diarios íntimos
4
Estados Unidos
4
Música
4
Música vocal (Jazz)
4
Novelistas ingleses
4
Arte
3
Aspectos sociales
3
Bailarines
3
Blues (Música)
3
Christmas music
3
Foreign films
3
Historia y crítica
3
Libros falsos
3
Literatura estadounidense
3
Motetes
3
Música de jazz
3
Operas
3
Songs (High voice) with piano
3
Songs (Medium voice) with piano
3
-
121
-
122
-
123
-
124
-
125
-
126
-
127por Miladinova, Daniela“…Targeting HER 2 for imaging and therapy in nuclear medicine has been used with a special emphasis on developing more powerful radiopharmaceuticals. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
128“…In this work, two human epidermal growth factor receptors, HER-1 and HER-2, were selected as biomarkers to enable the detection of breast cancer. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
129“…HER2‐targeted therapies improved progression‐free and overall survival in patients with HER2(+) breast cancers. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
130por Dent, S., Verma, Sh., Latreille, J., Rayson, D., Clemons, M., Mackey, J., Verma, Su., Lemieux, J., Provencher, L., Chia, S., Wang, B., Pritchard, K.“…Trastuzumab, a monoclonal antibody against the human epidermal growth factor receptor 2 (her2), was the first her2-targeted therapy that clearly demonstrated a significant clinical benefit for women with her2-overexpressing metastatic breast cancer (mbc). …”
Publicado 2009
Enlace del recurso
Enlace del recurso
Texto -
131por Sergina, Natalia V., Rausch, Megan, Wang, Donghui, Blair, Jimmy, Hann, Byron, Shokat, Kevan M., Moasser, Mark M.“…Oncogenic tyrosine kinases have proven to be promising targets for the development of highly effective anticancer drugs. However HER family tyrosine kinase inhibitors (TKIs) show only limited activity against HER2-driven cancers despite effective inhibition of EGFR and HER2 in vivo 1–8. …”
Publicado 2007
Enlace del recurso
Enlace del recurso
Enlace del recurso
Texto -
132por Pinhel, Isabel, Hills, Margaret, Drury, Suzanne, Salter, Janine, Sumo, Georges, A'Hern, Roger, Bliss, Judith M, Sestak, Ivana, Cuzick, Jack, Barrett-Lee, Peter, Harris, Adrian, Dowsett, Mitch“…However, we investigated the quantitative relation between ER and HER2 expression at both RNA and protein levels in HER2+ve and HER2-ve breast carcinomas. …”
Publicado 2012
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
133“…Human epidermal growth factor receptor 2 (HER2) is a tyrosine kinase transmembrane receptor that is overexpressed on the surface of 15%–20% of breast tumors and has been associated with poor prognosis. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
134por SAITO, MAYUKO, KAWAKAMI, YUJIRO, YAMASHITA, KENTARO, NASUNO, HIROSHI, ISHIMINE, YU, FUKUDA, KOICHIRO, ISSHIKI, HIROYUKI, SUZUKI, RYO, ARIMURA, YOSHIAKI, SHINOMURA, YASUHISA“…Serum HER2, the concentration of the extracellular domain of HER2 protein shed into the bloodstream, has the potential to supplement the use of IHC or FISH to determine HER2 status. …”
Publicado 2016
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
135por Zhang, Shu, Mukherjee, Seema, Fan, Xuejun, Salameh, Ahmad, Mujoo, Kalpana, Huang, Zhao, Li, Leike, Salazar, Georgina To'a, Zhang, Ningyan, An, Zhiqiang“…HER3/ErbB3 has emerged as a new therapeutic target for cancer. …”
Publicado 2016
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
136por Wang, Tonghui, Xu, Ye, Sheng, Shuyan, Yuan, Hua, Ouyang, Tao, Li, Jinfeng, Wang, Tianfeng, Fan, Zhaoqing, Fan, Tie, Lin, Benyao, Xie, Yuntao“…However, it is largely unknown whether HER2 somatic mutations are associated with survival in HER2‐negative breast cancer patients. …”
Publicado 2017
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
137por Mota, Jose Mauricio, Collier, Katharine Ann, Barros Costa, Ricardo Lima, Taxter, Timothy, Kalyan, Aparna, Leite, Caio A., Chae, Young Kwang, Giles, Francis J., Carneiro, Benedito A.“…Heregulins (HRGs) bind to the receptors HER3 or HER4, induce receptor dimerization, and trigger downstream signaling that leads to tumor progression and resistance to targeted therapies. …”
Publicado 2017
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
138por Dieci, Maria Vittoria, Bisagni, Giancarlo, Brandes, Alba A., Frassoldati, Antonio, Cavanna, Luigi, Giotta, Francesco, Aieta, Michele, Gebbia, Vittorio, Musolino, Antonino, Garrone, Ornella, Donadio, Michela, Rimanti, Anita, Beano, Alessandra, Zamagni, Claudio, Soto Parra, Hector, Piacentini, Federico, Danese, Saverio, Ferro, Antonella, Cagossi, Katia, Sarti, Samanta, Gambaro, Anna Rita, Romito, Sante, Bazan, Viviana, Amaducci, Laura, Moretti, Gabriella, Foschini, Maria Pia, Balduzzi, Sara, Vicini, Roberto, D’Amico, Roberto, Griguolo, Gaia, Guarneri, Valentina, Conte, Pier Franco“…We aimed to validate the prognostic stage in HER2-positive breast cancer patients enrolled in the ShortHER trial. …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
139por Gandullo‐Sánchez, Lucía, Capone, Emily, Ocaña, Alberto, Iacobelli, Stefano, Sala, Gianluca, Pandiella, Atanasio“…Despite impressive clinical benefit obtained with anti‐HER2‐targeted therapies, in advances stages, especially in the metastatic setting, HER2‐positive tumors remain incurable. …”
Publicado 2020
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
140por Ricci, Angela Dalia, Rizzo, Alessandro, Rojas Llimpe, Fabiola Lorena, Di Fabio, Francesca, De Biase, Dario, Rihawi, Karim“…However, subsequent studies on HER2 targeted therapies in this setting failed to meet their primary endpoints, and not all HER2-positive GC patients benefit from targeted approaches. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto